TFX TELEFLEX INC
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 96943 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY20.9%
TTM net income YoY192.9%
TTM EPS YoY212.3%
Revenue 3-yr CAGR-8.6%
Net income 3-yr CAGR-9.0%
Margins
Gross margin58.3%
Operating margin9.4%
Net margin13.5%
FCF margin3.9%
EBITDA margin18.7%
Returns
ROE8.3%
ROA4.3%
ROIC (approx.)3.8%
Asset turnover0.32x
Leverage & solvency
Liabilities / assets45.0%
Debt / equity0.46x
Current ratio2.01x
Interest coverage2.06x
Cash quality & payout
Operating cash flow / net income0.47x
Accruals ratio2.3%
Payout ratio19.3%
Capex / revenue2.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.99B | $1.70B | $1.71B | $2.79B | $2.81B |
| Cost of revenue | $871.96M | $662.16M | $672.33M | $1.26B | $1.26B |
| Gross profit | $1.12B | $1.04B | $1.04B | $1.53B | $1.55B |
| R&D expense | $144.78M | $109.02M | $113.63M | $153.82M | $130.84M |
| SG&A expense | $720.17M | $674.52M | $622.74M | $863.75M | $860.09M |
| Operating income | $118.37M | $103.65M | $258.73M | $499.73M | $628.10M |
| Interest expense | $100.22M | $83.51M | $85.01M | $54.26M | $56.97M |
| Pretax income | $24.55M | $26.29M | $185.39M | $445.92M | $559.47M |
| Income tax | -$33.98M | -$30.90M | $41.87M | $83.00M | $74.35M |
| Net income | -$905.64M | $69.67M | $356.33M | $363.14M | $485.37M |
| EBITDA | $296.11M | $265.19M | $406.83M | $730.32M | $865.46M |
| EPS (basic) | -20.30 | 1.49 | 7.58 | 7.74 | 10.38 |
| EPS (diluted) | -20.25 | 1.48 | 7.53 | 7.68 | 10.23 |
| Dividends declared per share | 1.36 | 1.36 | 1.36 | 1.36 | 1.36 |
| Weighted avg. shares (diluted) | 44.72M | 47.09M | 47.30M | 47.31M | 47.43M |
| Balance sheet | |||||
| Cash & equivalents | $378.56M | $247.85M | $222.85M | $292.03M | $445.08M |
| Receivables | $345.58M | $226.73M | $443.47M | $408.83M | $383.57M |
| Inventory | $404.39M | $306.77M | $626.22M | $578.51M | $477.64M |
| Current assets | $1.94B | $1.47B | $1.41B | $1.41B | $1.43B |
| PP&E, net | $498.28M | $308.46M | $479.91M | $447.20M | $443.76M |
| Goodwill | $2.31B | $1.99B | $2.91B | $2.54B | $2.50B |
| Intangibles | $1.52B | $1.35B | $2.50B | $2.31B | $2.29B |
| Total assets | $6.95B | $7.10B | $7.53B | $6.93B | $6.87B |
| Current liabilities | $762.03M | $649.36M | $606.75M | $581.49M | $680.12M |
| Short-term debt | $100.00M | $100.00M | $87.50M | $87.50M | $110.00M |
| Long-term debt | $2.54B | $1.56B | $1.73B | $1.62B | $1.74B |
| Total debt | $2.64B | $1.66B | $1.82B | $1.71B | $1.85B |
| Total liabilities | $3.82B | $2.82B | $3.09B | $2.91B | $3.12B |
| Shareholders' equity | $3.12B | $4.28B | $4.44B | $4.02B | $3.75B |
| Net debt | $2.26B | $1.41B | $1.59B | $1.42B | $1.41B |
| Cash flow statement | |||||
| Operating cash flow | $96.68M | $301.88M | $206.14M | $342.81M | $652.14M |
| Capital expenditure | $95.24M | $90.44M | $46.42M | $79.19M | $71.62M |
| Free cash flow | $1.45M | $211.44M | $159.72M | $263.62M | $580.52M |
| Investing cash flow | -$812.65M | -$63.36M | $27.26M | -$259.41M | $156.74M |
| Financing cash flow | $611.54M | -$421.93M | $38.54M | -$217.51M | -$715.82M |
| Depreciation & amortization | $177.74M | $161.53M | $148.10M | $230.59M | $237.36M |
| Stock-based compensation | $25.70M | $25.96M | $27.30M | $27.22M | $22.94M |
| Dividends paid | $60.27M | $63.54M | $63.90M | $63.79M | $63.65M |
| Share buybacks | $300.00M | $200.00M | $0 | $0 | — |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.